Loading company…
Zhimeng Biopharma is a Shanghai drug developer focused on treatments for chronic hepatitis B.
Zhimeng Biopharma develops medicines focused on chronic hepatitis B, including HBV nucleocapsid inhibitors, HBV RNA destabilizers and TLR8 agonists. Founded in 2017 in Shanghai, China, it is led by co-founder, president and CEO Huanming Chen, who previously worked at Shanghai Medicilon Biotech Co., Ltd. and BioDuro Technologies (Beijing) Co., Ltd. In November 2021 it raised CNY 350 million in Series B funding for Phase II studies of ZM-H1505R and Phase I studies of immunomodulators and KCNQ2/3 potassium channel openers.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in